Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
-
Cowen Expects Revance Therapeutics (RVNC) Weakness to Reverse, Reiterates $55 Price Target
-
Cowen Reviews Eight Potential Strategic Options Allergen (AGN); PT Lowered to $255
-
Allergan to Present at The Cowen and Company 38th Annual Health Care Conference
-
Drugmakers raise 2018 U.S. prices, stick to self-imposed limits
-
Allergan (AGN): Cutting PT To $280 From $400 - Cowen
-
Allergan (AGN) Growth Is On The Way And Investors Should Buy It - Cowen
-
Allergan (AGN): Buy Into The Weakness - Cowen
-
Allergan (AGN): Settlement Is Another Positive Step Towards Restasis Resolution - Cowen
-
Allergan (AGN): Durable Growth For Next Decade Plus - Cowen
-
Allergan to Present at Cowen and Company 37th Annual Health Care Conference
-
Allergan says U.S. tax reform unlikely in 2017, sees strong year
-
Allergan (AGN) Acquires Chase Pharmaceuticals in $125M + Milestones Deal
-
Allergan Acquires Chase Pharmaceuticals to Expand CNS R&D Pipeline and Build on Commitment to Alzheimer's Disease
-
Notable Analyst Rating Changes 4/18: (ESV) (BHP) (NGD) Upgraded; (CHD) (NTAP) (AGN) Downgraded
-
Pfizer (PFE) May Have Unrealistic Expectations for the Allergan (AGN) Integration - Cowen
-
Treasury Fact Sheet Should Not Prevent Pfizer (PFE)/Allergan (AGN) Deal - Cowen
-
Notable Analyst Rating Changes 8/3: (RAS) (RDS-A) (STAY) Upgraded; (BERY) (ACI) (COH) Downgraded
-
Fresh Off Generic Sale, Allergan (AGN) is Poised for Merger of Epic Proportions (AMGN) (ABBV)
-
Market Wrap: Chinese Stock Pressure Hits U.S. Markets; Durable Orders Outpace in June; Merger Monday
-
Pre-Open Stock Movers 07/27: (MAG) (TEVA) (AGN) Higher; (BLPH) (MYL) (GRUB) Lower (more...)
-
Allergan to Acquire Naurex
-
Notable Analyst Rating Changes 08/08: (ATVI) (ABX) (DK) Upgraded; (MYL) (HIBB) (SSYS) Downgraded
-
Allergen (AGN) Restasis Patent May be Issued in 4-5 Weeks - Cowen
-
Latest Qsymia Data Shapes Up Potential Bear Case for VIVUS (VVUS) and Peers (ARNA) (OREX)
-
George Soros' Hedge Fund Slashes Stake In Gold ETF (GLD), Raises Stake in Citi (C) and AT&T (T)
-
Notable Analyst Rating Changes 04/01: (HBAN) (LVS) (AGN) Upgraded; (BIDU) (IPG) (GHL) Downgraded
-
Allergan (AGN) Shares Jump Higher as Cowen Issues Intraday Upgrade
-
Notable Analyst Rating Changes 11/25: BDK, LEN, PSA, ANF Upgraded; MTL, SLG, CPB Downgraded
-
Cowen & Co Initiates Coverage on Allergan (AGN) with a Neutral

